Spyre Therapeutics Inc (SYRE) financials
Spyre Therapeutics revenue and earnings by year
Spyre Therapeutics's revenue was $886,000 in the fiscal year to December 31, 2023, down 62.0% from the year before. Net income was -$339 million, -38238.1% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 21.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 2 | 19 | 4 | 5 | 5 |
| Revenue growth | -62.0% | -87.6% | 382.0% | -25.3% | 12.5% | — |
| Operating income | -242 | -85 | -66 | -45 | -28 | -22 |
| Operating margin | -27348.0% | -3640.2% | -350.3% | -1169.3% | -531.7% | -473.3% |
| Net income | -339 | -84 | -66 | -44 | -27 | -22 |
| Net margin | -38238.1% | -3598.8% | -351.1% | -1140.6% | -523.3% | -468.8% |
| Diluted EPS | -$49.12 | -$24.86 | — | — | — | — |
| Free cash flow | -100 | -80 | -54 | -33 | -25 | -19 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open SYRE in Markets.
See also: SYRE returns
No forecast, no recommendation. This page describes Spyre Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.